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Chronic inflammation is a risk factor for lung cancer, and low-dose aspirin intake reduces
lung cancer risk. However, the roles that specific inflammatory cells and their products play
in lung carcinogenesis have yet to be fully elucidated. In mice, alveolar macrophage num-
bers increase as lung tumors progress, and pulmonary macrophage programing changes
within 2 weeks of carcinogen exposure. To examine how macrophages specifically affect
lung tumor progression, they were depleted in mice bearing urethane-induced lung tumors
using clodronate-encapsulated liposomes. Alveolar macrophage populations decreased to
≤50% of control levels after 4–6 weeks of liposomal clodronate treatment. Tumor burden
decreased by 50% compared to vehicle treated mice, and tumor cell proliferation, as mea-
sured by Ki67 staining, was also attenuated. Pulmonary fluid levels of insulin-like growth
factor-I, CXCL1, IL-6, and CCL2 diminished with clodronate liposome treatment. Tumor-
associated macrophages expressed markers of both M1 and M2 programing in vehicle
and clodronate liposome-treated mice. Mice lacking CCR2 (the receptor for macrophage
chemotactic factor CCL2) had comparable numbers of alveolar macrophages and showed
no difference in tumor growth rates when compared to similarly treated wild-type mice
suggesting that while CCL2 may recruit macrophages to lung tumor microenvironments,
redundant pathways can compensate when CCL2/CCR2 signaling is inactivated. Deple-
tion of pulmonary macrophages rather than inhibition of their recruitment may be an
advantageous strategy for attenuating lung cancer progression.
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INTRODUCTION
Lung cancer is responsible for 29% of all cancer deaths in North
America, making it more lethal than breast, colon, prostate, and
pancreatic cancer combined (1). Approximately 85% of lung can-
cer cases are smoking-related (2, 3), and tobacco smoke contains
both direct carcinogens and agents that promote the growth of
nascent tumors. Non-small cell lung cancer (NSCLC) constitutes
>75% of lung cancer cases, with adenocarcinoma (AC) being the
most frequently diagnosed subtype, regardless of smoking sta-
tus (4, 5). Lung cancer has long been associated with chronic
inflammatory disease. Limiting chronic inflammation may halt
the rapid growth and progression of this disease (6, 7) since long-
term, low-dose aspirin use reduces the risk of death from lung AC
by 45%. However, patients with non-AC subtypes of lung cancer
were not protected by aspirin use, suggesting that chronic inflam-
mation may be uniquely important for AC progression (7). In
addition, increased numbers of pulmonary macrophages corre-
late with poor prognosis in NSCLC patients (8–10), and alveolar
macrophage numbers also increase during lung tumor progression
in mouse models of AC (11, 12). Macrophage depletion early in
tumor formation decreases tumor multiplicity (12, 13) indicating
a role for inflammatory cells in tumor development even before
increased macrophage numbers are detected. Macrophages have
been described as obligate partners for breast cancer metastasis to
the lung in animal models, and activation of PPARγ in pulmonary
macrophages promotes lung cancer progression and metastasis
in a murine orthotopic model (14). Prolonged lung inflamma-
tion increases tumor multiplicity by promoting clonal expansion
of previously initiated cells (15), and chronic anti-inflammatory
drug therapy during chemical promotion decreases tumor multi-
plicity (13, 16). Chronic inflammation drives lung tumor growth
and progression in mouse models and human disease, and alveolar
macrophages facilitate much of this effect.
Alveolar macrophages produce numerous epithelial growth
factors in response to tissue damage, including insulin-like growth
factor-I (IGF-I) (8, 17). IGF-I receptor (IGF-IR) is required

























































Fritz et al. Macrophage depletion inhibits lung tumorigenesis
for anchorage-independent growth of epithelial cells and has
been studied in neoplastic proliferation for over 20 years. IGF-IR
inhibitors are an area of interest for lung cancer therapy (17, 18).
Macrophage IGF-I production is highly induced in response to
environmental insult (19). While resident alveolar macrophages
are a likely physiological source of lung IGF-I, this growth fac-
tor is undetectable in undifferentiated human peripheral blood
monocytes (20–22). Alternative macrophage programing occurs
early in lung tumorigenesis, corresponding with elevated IGF-I
production (23–26). Consistent with this association of tumor
growth and enhanced macrophage IGF-I production, transgenic
mice that produce twice as much IGF-I in bronchoalveolar lavage
fluid (BALF) compared to wild-type controls develop spontaneous
lung hyperplasias and adenomas after 12 months (27). Despite the
evidence linking lung inflammation, macrophage function, IGF-
I production, and tumor progression, the relationship between
macrophage-derived IGF-I and lung tumor cell proliferation
in vivo has not been fully explored. We previously showed that
BALF from lung tumor-bearing mice contains 3.5-times more
IGF-I than that from naïve mice, and macrophage-produced IGF-
I enhances neoplastic proliferation in vitro (26), indicating that
macrophage IGF-I production may play a major role in early lung
tumor progression.
Macrophages are selective targets for liposomal clodronate-
induced apoptosis because they aggressively phagocytize lipo-
somes (28). Their increased expression of phospholipases facil-
itates rapid release of clodronate from the liposome vehicle into
the phagocyte upon liposome engulfment (29–31). When admin-
istered intratracheally (IT), liposomes do not enter the systemic
circulation and deplete only alveolar macrophages (29, 31). Con-
versely, liposomes given intravenously (IV) systemically deplete
myeloid cells in the bone marrow, liver, spleen, and other tissues,
and reduce the number of circulating cells available for recruit-
ment to the lungs (32). Herein, we use a combination of IT and IV
administration of clodronate liposomes to deplete macrophages
from the lungs of tumor-bearing mice, and measure the result-
ing changes in lung pathophysiology by assessing primary lung
tumor growth, macrophage depletion, programing of remaining
macrophages, and BALF cytokine contents.
MATERIALS AND METHODS
MOUSE LUNG TUMORIGENESIS
Male A/J mice (6–8 weeks old) were purchased from Jackson Lab-
oratories (Bar Harbor, ME, USA), maintained on hardwood bed-
ding with a 12-h light/dark cycle, and given Teklad-8640 standard
laboratory chow (Harlan Teklad; Madison, WI, USA) and water
ad libitum. CCR2+/− breeding pairs on a BALB/cJ background
were kindly provided by Cara L. Mack, M.D. Department of Pedi-
atrics, School of Medicine, University of Colorado, Anschutz Med-
ical Center. BALB/cJ and CCR2−/− mice were bred in the Center
for Comparative Medicine (CCM) at the University of Colorado,
Anschutz Medical Center. A/J lung tumors were initiated by a sin-
gle 1 mg/g body weight intraperitoneal (IP) injection of urethane
dissolved in 0.9% NaCl (Alfa Aesar; Heysham, Lancashire, UK) as
described previously (33). CCR2−/− and wild-type BALB/cJ mice
were given six weekly 1 mg/g IP injections of urethane, a regi-
men shown to reproducibly induce lung tumors in this moderately
resistant strain (34). At the times indicated, mice were euthanized
by IP injection of sodium pentobarbital (Sigma Aldrich; St. Louis,
MO, USA). All animal procedures were performed in accordance
with the National Institutes of Health’s Guide for the Care and
Use of Laboratory Animals and were approved by the Institutional
Animal Care and Use Committee of the University of Colorado,
Anschutz Medical Campus.
BRONCHOALVEOLAR LAVAGE
Primary alveolar macrophages and lung protein exudates were
isolated by bronchoalveolar lavage (BAL), as previously described
(23, 35). The BALF fractions were separated by centrifugation,
BAL cells counted, and inflammatory macrophages, lymphocytes,
and neutrophils differentiated by Wright Giemsa (Fisher Scien-
tific) staining (23). BAL cell populations from both naïve and lung
tumor-bearing mice were composed predominantly of alveolar
macrophages (routinely >95%) (10).
MACROPHAGE DEPLETION BY CLODRONATE-ENCAPSULATED
LIPOSOMES
Dichloromethylene diphosphonate (clodronate, 2.5 g; Sigma) was
encapsulated in liposomes formed by a 25:1 w/w ratio of phos-
phatidylcholine:cholesterol (Sigma) as described (31), and the
resulting liposomes resuspended in 4 ml sterile PBS. Only 1–2% of
clodronate becomes encapsulated, yielding an estimated dose of
0.7–1.0 mg clodronate per 100µl of liposome suspension. Saline
(vehicle) liposomes and clodronate-encapsulated liposomes were
synthesized in parallel<2 weeks before use, stored at 4°C, and gen-
tly resuspended immediately before instillation or injection (31).
Clodronate liposomes for syngeneic transfer experiments were
synthesized or purchased from ClodronateLiposomes.org (The
Netherlands).
A/J mice bearing urethane-induced lung tumors were anes-
thetized by a single 50µl IP injection containing 100 mg/kg keta-
mine and 10 mg/kg xylazine (CU Clinical Pharmacy; Aurora, CO,
USA). Fifty microliters of vehicle or clodronate-containing lipo-
somes were instilled into the lungs via a ball-tip gavage needle bent
to a 30° angle and guided by a rodent laryngoscope (Penn Cen-
tury, Inc.). Follow-up liposome treatments were administered by
IV in all mice starting 2 days after IT instillation (100µl of vehi-
cle or clodronate liposomes administered IV via the tail vein) and
repeated once weekly for 5 weeks. IT administration of clodronate
is necessary to deplete resident alveolar macrophages, which are
not exposed to IV administration,but recruitment of bone marrow
macrophages to replenish the alveolar macrophage population can
be prevented by IV clodronate liposome ablation of bone marrow
monocytes (31).
TISSUE COLLECTION
Plasma was obtained by retro-orbital bleeding with heparin-lined
capillary tubes (Fisher Scientific) following administration of ter-
minal anesthesia, and stored at −80°C. Lungs were removed fol-
lowing BAL, the lobes dissociated, and tumors dissected from adja-
cent uninvolved lung under a dissection microscope, as described
(33). Tumor diameters were measured by digital calipers, and
tumors pooled in pre-tared microfuge tubes (one tube/mouse)
and weighed (tumor burden). Tumor dissection and evaluation
were conducted in a blinded fashion.
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IMMUNOHISTOCHEMISTRY, TUMOR GRADING, AND ASSESSMENT OF
PROLIFERATION
In a similarly treated group of mice, lungs were perfused via
the pulmonary artery with 0.9% NaCl, then gently inflated with
formalin through the cannulated trachea for 1 h. Lungs were
separated into individual lobes and dissected into 14 similarly
sized portions and fixed in formalin overnight (33). Lung pieces
were embedded in paraffin and sectioned (4µm). Sections were
processed as previously described, and incubated with anti-Ki67
primary antibody (1:200; Fisher Scientific) (33). Incubation with
a biotinylated goat anti-rabbit secondary (1:100; Vector Labora-
tories) was followed by incubation with horse-radish peroxidase
conjugated avidin, detection with 3,3-diaminobenzidine (Vector
Laboratories), and counterstain with hematoxylin. Sections were
evaluated at 400× magnification under an upright microscope
(BX41 Olympus), using Spot Advanced software (v4.0.1) to deter-
mine tumor area (33). The Ki-67 staining index was calculated by
dividing the number of positively staining cells in each tumor by
the corresponding tumor area (Ki-67+/cm2). This Ki-67 index was
averaged per animal and then per group. Serial lung sections were
stained with hematoxylin and eosin (Fisher Scientific), and lesions
graded as hyperplasia (Hyp), atypical adenomatous hyperplasia
(AAH), adenoma (AD), adenoma containing a focus of adeno-
carcinoma (ADwAC) or AC following the guidelines established
by Nikitin et al. (36) and using images found at the digital atlas
of virtual histological slides as examples (37). Grading was per-
formed in a blinded fashion by three individuals at a multiheaded
microscope and evaluated by a board certified pathologist (Daniel
T. Merrick). Particular attention was paid to nuclear morphology,
density of the lesion, and vessel involvement. We found that ade-
nomas and AC comprised the majority of lesions in this mouse
model, and squamous cell and neuroendocrine carcinomas were
not observed.
DETERMINATION OF MACROPHAGE PROGRAMING BY
IMMUNOFLUORESCENCE
Sections were deparaffinized and rehydrated prior to antigen
retrieval as described (23). Tissue sections were then incubated
overnight at 4°C with 1:50 dilution of anti-arginase I (ArgI,
Santa Cruz Biotechnology) primary antibody followed by 1:1000
dilution of Alexa 568-conjugated anti-goat secondary antibody.
A mixture of anti-NOS2 (BD Transduction Labs; 1:50 dilu-
tion) and anti-F4/80 (ABD-Serotec; 1:50 dilution) primary anti-
bodies were then applied for 1 h at 37°C, followed by 20 min
incubations with Alexa 488-conjugated anti-rabbit and Alexa
680-conjugated anti-rat secondaries. Nuclei were stained with
DAPI-containing mounting media (Vector Laboratories). Images
were obtained with a digital deconvolution microscopy imag-
ing system attached to a Zeiss Axioplan 2 epi-Fluorescence
upright microscope. Macrophages were identified by positive
F4/80 staining and morphology. Total pixel counts/macrophage
were calculated for ArgI, NOS2, and F4/80 immunofluorescence
(~50/animal) using ImageJ software (38), and ArgI and NOS2
values were normalized to F4/80 staining. To confirm ArgI+
M2 programing, adjacent sections were subjected to a simi-
lar IF protocol substituting an antibody against M2 marker
phosphoTyr641STAT6 (Cell Signaling, 1:50 dilution) for NOS2.
Fluorescence intensity was calculated similarly and phospho-
STAT6/ArgI ratios determined.
BALF IGF-I AND CYTOKINE DETERMINATION
Insulin-like growth factor-I concentrations in BALF were deter-
mined by enzyme-linked immunosorbant assay (ELISA) in a 96-
well format as directed (R&D Systems, Inc.). For lung cytokine
levels, BALF samples were concentrated 5× by centrifugation in
3 kDa molecular weight cut off YM-3 microcon spin-columns
(Millipore), and applied to Quantibody® mouse cytokine array
slides (Raybiotech, Inc.). Fluorescent Cy3-equivilent antibody sig-
nal was read by the CU Cancer Center Microarray Core Facility
using a Perkin Elmer Scan Array Ex glass slide laser scanner (Perkin
Elmer). Analytes were quantified by regression of log-transformed
data sets against within-run standard curves.
CCL2/CCR2 INVOLVEMENT IN LUNG TUMOR PROGRESSION
Tumorigenic mouse lung epithelial E9 cells (39) were maintained
in CMRL media (Invitrogen) supplemented with 10% fetal bovine
serum. For syngeneic transplant studies, 1× 106 log-phase E9
cells were suspended in 100µl of serum-free CMRL media (Life
Technologies) and injected subcutaneously (s.c.) into the shaved
right flanks of syngeneic male and female BALB/c (WT) or CCL2
receptor null (CCR2−/−) mice, a protocol previously shown to
generate rapidly growing tumors in nearly 100% of recipient
animals (40) Wild-type and CCR2−/− mice received vehicle or
clodronate-encapsulated liposomes by IV injection 1 day prior to
tumor inoculation (day −1), and once/week thereafter. Tumor
size was determined twice/weekly for 24 days, and tumor vol-
ume was calculated using the equation for an elliptical cone (as
recommended due to the non-spherical growth pattern of the
implants): V = (d2× l ×pi)/6, in which “d” is the smallest diam-
eter, and “l” the largest. Tumor-bearing mice were euthanized and
flank tumors removed and weighed. The experiment was per-
formed twice, with 5–6 mice/group/repetition. Previous studies
showed that both macrophage conditioned media (MΦCM; 1:1
mixture of fresh media with media harvested after 24 h incuba-
tion with MH-S murine alveolar macrophage cells) and/or IGF-I
stimulated in vitro proliferation of cultured mouse lung epithelial
cells. To determine if this was also true for E9 cells, subconflu-
ent cultures were incubated with MΦCM or 50 ng/ml IGF-I for
48 h, harvested, and relative cell numbers were compared using
CellTiter96® proliferation assays (Promega).
STATISTICAL ANALYSIS
Continuous variables were analyzed by two-way ANOVA with
Bonferroni post hoc comparison to determine significant differ-
ences between groups and account for multiple inter-group com-
parisons. One-way ANOVA with student Newman–Keuls post hoc
analysis was used to determine significant differences between
three or more groups while Student’s two-tailed independent t -
test was used when only two groups were compared, with Welch’s
correction for unequal variances when appropriate. All statistics
including Spearman correlations were performed using Prism 5.0
software (Graphpad; La Jolla, CA, USA). Data are presented as
mean± SEM, unless otherwise indicated. In all analyses, p< 0.05
was considered to be statistically significant.
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FIGURE 1 | (A) Alveolar macrophage numbers increase as a function of
tumor growth. Alveolar macrophage (AM) content was determined in
naïve () and urethane-treated () A/J mice as a function of time (left
axis). Tumor burden, determined by tumor weight (©, right axis), increased
similarly over time (**p< 0.01 tumor-associated vs. naïve alveolar
macrophages). Few tumors were detected in naïve mice at any time point
(data not shown). (B–E) Mice (n= 4–6 mice/group) bearing
urethane-induced lung tumors were treated with clodronate-containing
liposomes (black bars) or the vehicle control (gray bars) for 5 weeks prior to
lung harvest at 32 weeks and 44 weeks. (B) Alveolar macrophages are
depleted by clodronate treatment (**p<0.01 vs. vehicle) at both 32 and
44 weeks. (C) Tumor burden decreases with macrophage depletion at
44 weeks, but not 32 weeks. (D) Tumor number remains constant
regardless of age or clodronate treatment. (E) Tumor multiplicity at
44 weeks broken down by tumor size. Significant difference (*p<0.05)
between treatment groups occurred only in tumors >4 mm in diameter.
RESULTS
Tumor burden and alveolar macrophage numbers (obtained by
lavage) increased similarly over time in urethane-treated A/J mice
(Figure 1A), while alveolar macrophage numbers changed little
over the same time course in naïve mice. Few tumors are detected
in naïve mice (data not shown). Liposomal clodronate significantly
depleted alveolar macrophages in tumor-bearing mice [harvested
32 (37%) and 44 (48%) weeks after urethane injection compared
to vehicle liposome treated, tumor-bearing mice (Figure 1B)].
Tumor burden at the 44-week time point decreased by ~50% with
clodronate treatment (Figure 1C) while tumor number did not
change (Figure 1D). Comparing tumor weight at 44 weeks to
that of mice sacrificed at 32 weeks suggests that tumors did not
regress with clodronate treatment, but simply did not grow as
rapidly (Figure 1C). A significant decrease in tumors with diame-
ter >4 mm was detected, indicating that clodronate preferentially
slowed the growth of larger tumors (Figure 1E). Immunohisto-
chemical staining of Ki67, a marker of cell division, decreased
by >50% in tumors from 44-week clodronate-treated mice com-
pared to the vehicle liposome-treated controls (Figures 2A,B),
affecting tumors of varying size (Figure 2D). Similar numbers of
hyperplasias, AAH, adenomas, adenomas with AC-like foci, and
AC (Figures 2C,E) were detected in the lungs of both vehicle and
clodronate-treated mice.
Programing in tumor-associated macrophages (TAMs) was
examined by immunofluorescence to determine whether clo-
dronate liposomes targeted a specific subset of macrophages in
mice bearing 44-week lung tumors. TAMs in this study exhib-
ited a mixed M1/M2 phenotype characterized by both NOS2 (an
M1 programing marker) and ArgI (an M2 programing marker)
expression (Figure 3A). Because earlier studies showed predomi-
nantly NOS2+macrophages in this model at this late time point, a
second M2 marker, phosphoSTAT6, was analyzed confirming the
presence of M2 markers (Figure 3B). Previously, we determined
that human lung TAMs express similar mixed (NOS2+CD206+)
programing (23). We saw no large-scale differences in program-
ing marker expression between vehicle and clodronate exposed
macrophages (Figure 3C), and ArgI/phosphoSTAT6 ratios were
also similar between groups (Figure 3C) suggesting that the TAMs
in this model are similarly programed, and this programing is not
affected by clodronate exposure.
Cytokine and IGF-I levels were measured in BALF from vehicle
and clodronate-treated, tumor-bearing mice 44 weeks after ure-
thane. BALF levels of GM-CSF, IFN-γ, IL-1α, IL-1β, IL-2, IL-4, IL-
5, IL-9, IL-10, IL-12, IL-17, M-CSF, and RANTES were unchanged
by clodronate treatment (data not shown). IL-3, IL-13, and TNF-α
contents were below the limit of detection in all samples (data not
shown). Clodronate treatment significantly decreased levels of IL-
6, CCL2, CXCL1, and IGF-I, while VEGF levels increased 1.5-fold
(Figures 4A,B). Serum levels of IGF-I did not change with clo-
dronate exposure (Figure 4B). Levels of IGF-I, CXCL1, IL-6, and
CCL2 were higher in BALF from tumor-bearing mice than naïve
mice 32 weeks after urethane treatment, but VEGF levels were
unchanged (Figure 4C). IGF-I levels correlate significantly with
BAL macrophage numbers in naïve and tumor-bearing animals
(Figure 4D, p< 0.0001) as well as in animals exposed to vehicle
and clodronate-containing liposomes (Figure 4E, p< 0.03). Acti-
vated macrophages produce IL-6, CCL2, CXCL1, and IGF-I, but
concomitant production of all four signaling molecules also indi-
cates a “mixed phenotype” of macrophages since IL-6 and IL-8
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FIGURE 2 | Effects of clodronate treatment on tumor growth and
progression. (A) Representative Ki67 IHC on tissue sections from similar
sized tumors from vehicle (left) and clodronate (right) treated mice (400×
final magnification). Red arrows point to positively stained tumor cells.
(B) Ki-67 index was calculated as the average number of Ki-67+ cells/cm2
tumor area for each tumor in each group (mean±SEM, **p<0.01 vs.
vehicle). (C) Representative examples of each tumor grade (400× final
magnification). (D) Ki67 index as a function of tumor size at 44 weeks in
saline and clodronate-treated mouse lung tumors. Significant differences
were seen in the number of Ki67+ cells in the smaller lung tumors.
(E) Percent of each lesion type was calculated/mouse. No significant
differences were detected.
(human ortholog of murine CXCL1) are most often associated
with M1 programing and IFG-I and CCL2 with M2 programing.
Vehicle treated mice secreted 6.5-fold more CCL2 into BALF
compared to clodronate-treated mice (Figure 4A). As CCL2 is
a chemotactive factor for monocytes and could be integral in the
recruitment of macrophages to the site of tumors development, we
tested whether ablation of CCL2/CCR2 signaling affected tumor
growth in a syngeneic transplant model. Transformed mouse lung
epithelial E9 cells were injected into the flanks of immunocompe-
tent syngeneic BALB/cJ wild-type or CCR2−/−mice. After tumors
were established, mice were subjected to systemic liposome-based
macrophage depletion. There were no significant differences in
tumor growth among the vehicle treated wild-type, vehicle treated
CCR2−/−, or clodronate-treated CCR2−/− mice. However, flank
tumors in wild-type mice receiving clodronate liposomes grew
significantly slower (Figure 5A). We previously showed that
macrophage conditioned media (MΦCM) increases proliferation
of mouse lung epithelial cells in vitro, and IGF-I is the major
component in MΦCM that contributes to this proliferative effect
(26). Both MΦCM and IGF-I increased E9 proliferation by more
than threefold over control media suggesting that the inhibition
of syngeneic tumor growth, resulting from systemic macrophage
depletion may be due to decreased macrophage production of
IGF-I (Figure 5B).
Ablation of CCL2/CCR2 signaling did not affect the growth
of syngeneically transplanted E9 cells, and although there was a
slight, but not significant trend of slower growth of the E9 tumors
in the CCR2−/− mice, the effect was not as dramatic as that seen
with clodronate treatment. In addition, tumor growth in CCR2−/−
mice was not significantly slowed by clodronate exposure. To test
whether CCL2/CCR2 signaling is required for the de novo devel-
opment of tumors in the lung, wild-type and CCR2−/− mice were
initiated with six weekly urethane injections. Lung tumors were
harvested, counted, and tumor burden (by weight) assessed at 20,
32, 38, and 42 weeks after the initial urethane exposure. No sig-
nificant decreases in tumor number, tumor burden, or alveolar
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FIGURE 3 | Immunofluorescent determination of macrophage
programing. (A) Alveolar macrophage ArgI (red), NOS2 (green), and F4/80
(blue) expression and the merged image (showing co-localization) in
tumor-bearing mice treated with saline or clodronate-containing liposomes.
(B) ArgI (red), STAT6 (green), and F4/80 (blue) expression and the merged
image showing co-localization in tumor-bearing mouse lung treated with
saline or clodronate-containing liposomes. (C) Pixel counts/macrophage of
ArgI (red) or NOS2 (green) normalized to F4/80 (blue) or STAT6 (blue)/ArgI
ratios in saline (open bars) or clodronate (cross-hatched) liposome-treated
lung (mean±SEM, n=135–150 macrophages/group).
macrophage numbers were detected in CCR2−/− mice at any time
point (data not shown). Results from the 42-week time point are
shown in Figures 5C–F. Not only did CCR2−/− mice show simi-
lar number of alveolar macrophages and lung tumors at this late
time point, there was a significant increase in lung tumor diam-
eter in the CCR2−/− mice. As CCL2/CCR2 signaling was ablated
in the CCR2−/− mice, either a redundant pathway compensates
for macrophage recruitment to the lung or resident macrophages
proliferate to compensate for the lack of CCL2/CCR2-mediated
macrophage recruitment.
DISCUSSION
Depletion of pulmonary macrophages by nearly 50% decreased
the growth of the largest lung ACs in the A/J urethane model.
Decreased Ki67 staining indicated that cell division slowed as a
result of macrophage depletion in vivo, an observation comple-
menting previous results showing that macrophage co-culture and
exposure to macrophage conditioned media increased tumor cell
proliferation in vitro (26). Macrophage depletion did not cause
tumor regression as tumor number and stage did not change after
clodronate treatment. TAMs produce signals that support tumor
growth and promote tumor cell survival. When TAMs are depleted,
production of these signals decreases causing a reduction in tumor
cell proliferation. Clodronate exposure decreased BALF levels of
IGF-I, IL-6, CXCL1, and CCL2 and increased VEGF levels while
not affecting most of the other factors examined (largely TH1 and
TH2-associated cytokines), suggesting that alveolar macrophages
may not be their primary source in murine lungs. IGF-I involve-
ment in lung tumorigenesis is well established, and the positive
correlation of pulmonary BAL IGF-I levels with macrophage num-
bers (Figures 4C,D) suggests that macrophage production of IGF-
I is important in maintaining tumor growth. The decrease in IGF-I
levels caused by clodronate-induced macrophage depletion may be
partially responsible for slowing lung tumor growth in vivo, which
is consistent with our previous observations of IGF-I mediation
of a significant portion of MΦCM induced lung tumor cell prolif-
eration in vitro. The increased BALF VEGF levels detected in the
clodronate-treated animals may occur in response to clodronate-
induced macrophage apoptosis, as VEGF expression is induced in
macrophages that clear apoptotic cells by efferocytosis (41, 42).
The remaining healthy alveolar macrophages may express more
VEGF as they clear the apoptotic macrophages, resulting from
clodronate depletion.
The attenuation of CCL2 production caused by clodronate
liposome exposure suggested that monocyte recruitment might
also play a role in tumor progression. CCL2 (MCP-1; monocyte
chemotactic protein-1) is involved in recruitment of monocytes
(43), T cells (44), and dendritic cells (45) to areas of inflamma-
tion induced by tissue injury or infection. High levels of CCL2
are associated with poor prognosis in breast cancer (46) and
pancreatic cancer (47). However, Zhang et al. (48) found that
CCL2 over-expression is associated with improved survival in
NSCLC patients indicating that CCL2/CCR2 signaling may have
different roles in different tissues. To determine whether CCL2
signaling affected lung tumor growth in mice, syngeneic mouse
lung tumor cells were transplanted into wild-type and CCR2−/−
mice. Ablation of CCL2/CCR2 signaling had no effect tumor
growth, and the lack of CCL2/CCR2 signaling actually nullified
the growth inhibitory effects of clodronate liposomes for reasons,
which remain to be determined. Because E9 cells are already trans-
formed and do not require a progression phase for tumor growth
and because alveolar macrophages differ in function and response
from macrophages present near subcutaneous tumors (49), we
tested whether CCL2/CCR2 signaling was required for de novo
lung tumor formation. BAL macrophage content and tumor num-
bers from urethane-exposed CCR2−/− and wild-type mice were
similar between genotypes at each time point. A slight, but sig-
nificant increase in tumor size in the CCR2−/− mice compared
to wild-type littermates was detected at the 44-week time point,
which is consistent with the poorer survival observed in human
NSCLC patients with low-CCL2 expression (48). Macrophages
are known to produce CCL2 in response to IL-4/IL-13 stimulation
(50), and the increase in CCL2 production we detected during
lung tumorigenesis indicates that there is a Th2 response occurring
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FIGURE 4 | Effects of macrophage depletion on BAL cytokine
content. Cytokine levels were determined in BALF from naïve (white
bars), vehicle liposome (gray bars), or clodronate liposome (black bars)
treated mice 44 weeks after urethane treatment. (A) Clodronate
administration decreased IL-6, CCL2, and CXCL1 in BALF, while VEGF
increased 1.5-fold. Data presented as mean±SEM, n= 4–6 mice/group
(*p<0.05 vs. vehicle treated mice). (B) BALF IGF-I levels decreased
with clodronate treatment in AC-bearing mice (***p< 0.001 vs.
vehicle). (C) Fold change in BALF IGF-I, IL-6, CXCL1, CCL2, and VEGF
levels in age-matched naïve and tumor-bearing mice 32 weeks after
urethane exposure (*p<0.05) (D) Correlation between IGF-I and BAL
macrophage number in naïve and urethane-treated mice 24 and
32 weeks after urethane treatment (Spearman ρ=0.8055, p< 0.0001).
(E) Correlation between IGF-I and BAL macrophage number in 44-week
urethane mice treated with saline and clodronate liposomes (Spearman
ρ=0.4990, p<0.0031).
in lungs during tumor formation. The CCL2 receptor (CCR2) is
expressed only in monocyte-lineage cells and T lymphocytes, so
CCL2 is unlikely to directly affect neoplastic epithelial cells (9).
CCL2 may regulate macrophage recruitment following lung injury,
as CCL2 levels in BALF are elevated just prior to the macrophage
influx that follows chemically induced pneumotoxicity (51). The
similar alveolar macrophage content in tumor-bearing lungs from
both wild-type and CCR2−/− mice suggests that either there are
redundant macrophage recruitment pathways at play in the lung
tumor microenvironment or that the increased number of TAMs
results from proliferation of resident macrophages rather than
recruitment as has been reported (52).
High-serum IL-6 levels correlate with poor survival and poor
response to chemotherapy in NSCLC patients (53, 54). IL-6 is an
inflammatory cytokine produced primarily by T cells and M1-
programed macrophages to stimulate immune response to injury
and trauma. IL-6 may be required for M1 programing in some
macrophages, but IL-6 production can induce M2 programing
in certain systems to limit existing inflammation (55). Recently,
Fernando et al. showed that M2 programing is enhanced by IL-6
exposure in cultured macrophages and suggested that IL-6 aug-
ments cytokine expression during both M1 and M2 programing
(56). Similar to our findings, Karnevi et al. report that human
pancreatic tumor-educated macrophages display mixed M1/M2
programing and produce increased IL-6 and IL-8 (57). Pine et al.
report that increased IL-6 and IL-8 production are associated with
increased lung cancer risk (58), and IL-6 and IL-8 are both associ-
ated with increased NSCLC cell proliferation (59) although neither
directly induces increased cell division. Human IL-8 (CXCL8)
and murine keratinocyte-derived chemokine CXCL1 (KC) are
orthologous in function. CXCL1 production is high in murine
alveolar macrophages (60, 61), but not in peritoneal macrophages
(62–65). The specific combination of cytokines and surfactant
proteins intrinsic to the lung make alveolar macrophages function-
ally unique compared to macrophages from other tissues. Lung
production of IL-8/CXCL1 is induced by inflammatory stimuli
through NF-κB and AP-1 activation (63, 65), and both NSCLC
cells and macrophages express IL-8/CXCL1. IL-8/CXCL1 is a pro-
angiogenic factor as well as a chemotactic factor for neutrophil
recruitment to the lungs during emphysema and lung cancer. Few
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FIGURE 5 | Clodronate reduces syngeneic implant growth in
wild-type (WT), but not CCR2−/− mice. (A) E9 cells were injected into
the flank of female BALB/cJ (WT) or CCR2−/− mice. After tumors were
established (8 days post injection), clodronate-containing or vehicle
liposomes were injected IV once/week until sacrifice. Tumors were
measured 2×/week and volumes calculated. Clodronate liposome
treatment (Cdr) decreased tumor growth in wild-type mice (*p<0.05,
n=10–12 mice/group from two independent experiments). (B) E9 cells
were cultured in serum-free media (vehicle), 50 ng/ml IGF-I containing
media, or macrophage conditioned media (MΦCM). Cell density was
determined by MTS and graphed as fold-increase over control
(mean±SEM, ***p<0.001 vs. control). (C–F) Wild-type BALB/cJ and
CCR2−/− mice were injected with 1 mg/g urethane once/week for 6 weeks.
BALF and tumors were harvested 42 weeks after the first injection and
BAL macrophages (×1000) counted, and lung tumors counted, measured,
and weighed (mean±SEM, *p<0.05 vs. wild-type, n=5).
neutrophils were detected in the lungs of vehicle or clodronate
liposome-treated tumor-bearing mice (data not shown), so we
could not determine whether clodronate treatment altered their
numbers further.
Macrophage programing in mouse lung is homogeneous, prob-
ably due to the small size of the organ. As urethane-exposed A/J
mice form>30 tumors/mouse and these tumors are spread evenly
throughout the lobes, alveolar macrophages are exposed to tumor
produced factors throughout the lung. The A/J urethane model
of lung cancer is unique among most murine lung tumor mod-
els in that TAMs surrounding late-stage ACs express high levels
of NOS2 and little ArgI, indicating that they are primarily M1-
programed (23, 24, 34). However, BALF cytokine levels in these
mice indicate that macrophage programing might be more com-
plex. Although ArgI expression decreases as tumors progress, pro-
duction of certain M2-associated signaling molecules (i.e., IGF-1,
CCL2) increases. When these mice were exposed to either vehi-
cle or clodronate-containing liposomes, we detected an increase
in both ArgI and phosphoSTAT6 expression (M2 programing
markers) in the same macrophages that maintained high-NOS2
expression. The M1/M2 classification represents a continuum
of plasticity and does not encompass the functional diversity of
macrophages (66), and the measurement of biomarker expression
rather than activity and/or function may not yield an accurate
picture of macrophage programing. In our study, we detected
NOS2+ArgI+ macrophages, but we did not measure NO levels
or determine arginase activity, so although both enzymes were
present, we do not know that both were active in the same cells.
The presence of phosphoSTAT6 in these TAMs indicates that they
were more “M2-like” and the presence of CCR2 and IGF-1 in the
BALF supports this. Although there were fewer macrophages in the
clodronate-treated lungs, the ratio of ArgI to NOS2 remained con-
stant in the remaining cells indicating that the remaining tumor
microenvironment and not macrophage depletion continued to
affect the programing of the remaining macrophages.
Our previous studies indicated that TAMs near human lung
AC also expressed M1 and M2 markers simultaneously (24), and
others have seen similar mixed phenotypes in TAMs in pancre-
atic (57) and gastric cancer (67). Mixed macrophage programing
was also demonstrated in the resolution of liver fibrosis (68) and
pulmonary fibrosis (69) and in the early stages of diet induced
obesity (70). These mixed populations could be due to catch-
ing the macrophages as they change from one programing state
to another as in the resolution of a disease, or as they respond
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to conflicting microenvironmental signals. The detection of both
inflammatory and anti-inflammatory cytokines in BALF from
these mice indicates that these macrophages do not follow the
canonical roles of M1 or M2 macrophages. Further research to
determine phagocytic and efferocytic activity, proliferative capac-
ity, and gene expression of TAMs from tumor-bearing mice before
and after exposure to vehicle and clodronate liposomes is neces-
sary to characterize this novel macrophage population. The ability
of clodronate liposomes to deplete pulmonary macrophages may
be enhanced by changing the composition of the liposome deliv-
ery vehicle to more effectively and specifically target TAMs that
accumulate in the lungs of tumor-bearing mice. These mixed phe-
notype macrophages may express scavenger receptors such as the
mannose receptor, so adding mannose to the liposome surface
may increase their uptake, resulting in greater depletion (71). Also,
M2 macrophages exhibit enhanced efferocytosis (72) while M1
macrophages are professional phagocytes, so the presence of phos-
phatidyl serine in the liposome membrane to mimic apoptotic
cells and/or lipopolysaccharides on the exterior of the liposome
to mimic bacterial cell walls may lead to enhanced uptake and
possibly increased macrophage depletion. As IGF-I signaling acti-
vates survival factors such as AKT in tumor cells (26), macrophage
depletion and the subsequent decrease in BALF IGF-I levels may
make tumors more sensitive to therapy-induced death. Although
macrophage depletion cannot eliminate lung tumors, it may sensi-
tize tumors to classic chemotherapeutics and radiation by remov-
ing both macrophage-produced survival factors from the lung
prior to cytotoxic therapies and growth promoting signals such as
IGF-I during tumor recovery. Finally, by decreasing the permissive
nature of the tumor microenvironment, macrophage depletion
may allow the host’s own defenses to recover and eliminate tumor
cells.
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